Nature Communications (Sep 2022)
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
Abstract
Understanding how small molecules bind to pathological aggregates is of importance for therapeutic and diagnostic development in diseases such as Parkinson’s Disease. Here, the authors reveal a binding site of anle138b to lipid-induced α-synuclein fibrils.